



# **Consolidated Financial Results** **for the Six Months Ended June 30, 2025** **[IFRS] (Summary)**

August 6, 2025

Company name: Nissha Co., Ltd.  
 Stock exchange listing: Tokyo Stock Exchange  
 Code number: 7915  
 URL: <https://www.nissha.com/english>  
 Representative: Junya Suzuki, Chairman of the Board and Group CEO  
 Contact: Daisuke Inoue, Director of the Board, Senior Executive Vice President, Interim CFO  
 Phone: +81-75-811-8111  
 Scheduled date of filing semi-annual securities report: August 7, 2025  
 Scheduled date of commencing dividend payments: September 1, 2025  
 Availability of supplementary briefing material on financial results: Available  
 Schedule of financial results briefing session: Scheduled (for institutional investors)

(Amounts of less than one million yen are rounded down)

## **1. Consolidated Financial Results for the Six Months Ended June 30, 2025 (January 1, 2025 to June 30, 2025)**

(1) Consolidated Operating Results (cumulative) (% indicates changes from the previous corresponding period)

	Net sales		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Total comprehensive income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Six months ended June 30, 2025	97,049	(2.6)	2,693	(36.9)	1,218	(79.7)	361	(91.6)	129	(97.0)	(4,018)	—
Six months ended June 30, 2024	99,661	20.1	4,266	—	6,007	452.4	4,320	449.1	4,258	431.6	15,078	95.1

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Six months ended June 30, 2025	2.72	—
Six months ended June 30, 2024	88.04	—

- (Notes) 1. The Company finalized the provisional accounting treatment pertaining to business combination in the six months ended June 30, 2025, and reflected the details of the finalization of the provisional accounting treatment on figures related to the six months ended June 30, 2024.
2. The percentage change in operating profit from the previous corresponding first half is written as "-" because it is 1,000% or more.

## **(2) Consolidated Financial Position**

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
	Million yen	Million yen	Million yen	%
As of June 30, 2025	239,655	111,055	108,829	45.4
As of December 31, 2024	251,946	115,212	114,028	45.3

(Note) The Company finalized the provisional accounting treatment pertaining to business combination in the six months ended June 30, 2025, and reflected the details of the finalization of the provisional accounting treatment on figures related to the fiscal year ended December 31, 2024.

## 2. Dividends

	Annual dividends				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended December 31, 2024	—	25.00	—	25.00	50.00
Fiscal year ending December 31, 2025	—	25.00			
Fiscal year ending December 31, 2025 (Forecast)			—	25.00	50.00

(Note) Revision of cash dividend forecast most recently announced: No

## 3. Consolidated Financial Results Forecast for the Fiscal Year Ending December 31, 2025 (January 1, 2025 to December 31, 2025)

(% indicates changes from the previous corresponding period)

(% indicates changes from the previous corresponding period)

	Net sales		Operating profit		Profit before tax		Profit attributable to owners of parent		Basic earnings per share
Full year	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
	190,800	(2.5)	6,600	20.3	4,600	(26.1)	2,500	(35.4)	52.80

(Notes) 1. Revision of consolidated financial results forecast most recently announced: Yes

2. Changes from the previous corresponding period are calculated based on figures after retrospective adjustments, reflecting the finalization of the provisional accounting treatment related to the business combination conducted in the six months ended June 30, 2025.

## **Qualitative Information on Consolidated Financial Results for the Period under Review**

The provisional accounting treatment for the business combination with Isometric Intermediate LLC and its group companies, conducted on March 1, 2024, was finalized during the six months ended June 30, 2025. Accordingly, revised figures based on the finalization of the provisional accounting treatment have been used for the comparative analysis with figures for the six months ended June 30, 2024.

### **Explanation of operating results**

The Group's Mission is to use the diverse capabilities of its people and core technologies as an engine for growth to create highly competitive, feature-rich products and services that realize customer value and contribute to better lives for all.

Guided by this Mission, we established our Sustainability Vision as our long-term vision for 2030, and aim to create economic and social value by contributing to solving global social issues in the priority markets of Medical, Mobility, and Sustainable Materials, with the integration and orchestration of the diverse talents of our people and our technologies. Correspondingly, we have formulated and implemented the 8th Medium-term Business Plan that sets forth the medium-term plan to be achieved in the three years from fiscal 2024 to 2026 and a strategy to get there, reflecting backwards the Sustainability Vision. Aiming to achieve stable growth and increased capital efficiency, we will improve and stabilize profitability by strengthening the business portfolio we have built up to date.

During the six months ended June 30, 2025, the global economy continued to trend toward recovery, though uncertainty over the future heightened due to developments relating to the U.S. tariff policies and geopolitical risks. In the United States, the economy slightly slowed but remained firm due to widespread uncertainty concerning tariff policies. In Europe, the economy trended toward recovery against the backdrop of a rush demand before the imposition of the additional U.S. tariffs and an increase in consumer spending. In China, although the economy showed a moderate recovery driven by government economic stimulus measures, foreign demand remained sluggish, and the overall economic recovery lacked momentum. Meanwhile, the Japanese economy showed signs of a moderate recovery, constrained by sluggish external demand and other factors.

Under these conditions, during the six months ended June 30, 2025, product demand remained steady in the Industrial Materials and the Medical Technologies segments, and the company acquired in the pharmaceutical business during the current period began to contribute to earnings. In the Devices segment, product demand for tablets exceeded expectations due to a surge in purchase ahead of the implementation of the additional U.S. tariffs. However, it declined compared to the same period of the previous year, when demand was firm by new product launches. In addition to these, foreign exchange loss was recorded under other expenses.

As a result, regarding the financial results for the six months ended June 30, 2025, net sales were ¥97,049 million (a decrease of 2.6% as compared to the same period of the previous year), operating profit was ¥2,693 million (a decrease of 36.9% as compared to the same period of the previous year) and profit attributable to owners of parent was ¥129 million (a decrease of 97.0% as compared to the same period of the previous year).

Following is an overview by business segment.

#### **Industrial Materials**

In the Industrial Materials segment, we mainly offer proprietary technologies that enable to create added value on the surfaces of various materials. IMD, IML, and IME, which facilitate simultaneous in-mold decoration, design and function adding of plastic products, are extensively used in mobility components and home appliances in global markets. Also, the metallized paper, which unites the properties of metallic luster and printing friendliness, has the largest market share in the

industry as sustainable materials for beverages and foods on a global basis.

During the six months ended June 30, 2025, demand for mobility components in the field of decorations remained firm, and that for home appliances and items such as the metallized paper in the field of sustainable materials was steady. These demand trends helped to increase net sales year on year, while operating profit decreased year on year mainly due to upfront costs associated with new products for mobility components.

As a result, segment sales for the six months ended June 30, 2025 were ¥37,570 million (an increase of 0.9% as compared to the same period of the previous year). Segment profit (operating profit) was 2,169 million (a decrease of 19.6% as compared to the same period of the previous year).

#### Devices

In the Devices segment, we produce components and module products that pursue precision and functionality. Our main products, film-based Touch Sensors are widely adopted mainly in tablets, handheld terminals (logistics related), mobility components, and gaming devices in global markets. In addition, we offer gas sensors that can detect gas conditions, along with other products.

During the six months ended June 30, 2025, although the demand for tablets exceeded expectations due to a surge in purchase ahead of the implementation of additional U.S. tariffs, it declined compared to the same period of the previous year, when demand was firm by new product launches. Accordingly, net sales and operating profit decreased year on year, despite improvements in efficiency and productivity following the revision of the production structure.

As a result, segment sales for the six months ended June 30, 2025 were ¥29,752 million (a decrease of 18.0% as compared to the same period of the previous year). Segment profit (operating profit) was ¥ 1,097 million (a decrease of 41.4% as compared to the same period of the previous year).

#### Medical Technologies

The Medical Technologies segment is a business segment that offers high-quality and value-added products in medical devices and other related markets to contribute to healthy and affluent life. The segment currently provides contract design/development and manufacturing services for major medical device manufacturers, especially for those in North America and Europe, with products such as surgical instruments for minimal invasive medical treatments and medical wearable sensors used for a wide range of therapeutic areas. In addition to these, the segment manufactures and sells its own brand products to medical institutions.

During the six months ended June 30, 2025, both net sales and operating profit increased year on year, driven by steady demand for our mainstay contract design/development manufacturing services for medical devices and the contribution to earnings from companies acquired on March 1, 2024, among other factors.

As a result, segment sales for the six months ended June 30, 2025 were ¥23,459 million (an increase of 6.5% as compared to the same period of the previous year). Segment profit (operating profit) was ¥1,267 million (an increase of 23.2% as compared to the same period of the previous year).